Clinical Implications of Angiotensin II Type 1 Receptor Antibodies in Antibody-mediated Rejection Without Detectable Donor-specific HLA Antibodies After Renal Transplantation

Lee, J.; Park, Yongjung; Kim, B.S.; Kim, H.J.; Kim, Y.S.; Huh, Kyu Ha

doi:10.1016/j.transproceed.2014.11.055

Cited by 24 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early reports of the significance of anti‐AT1R antibodies in transplantation were limited primarily to patients who were selected for AT1R testing because of functional decline of their allograft in the absence of antibodies to HLA . The early publications suggest that anti‐AT1R antibodies can be associated with AMR and/or might contribute to poorer long‐term outcomes in kidney transplantation . However, Deltombe et al found no increased tendency to acute rejection episodes or long‐term graft outcomes among kidney recipients who were positive for anti‐AT1R prior to transplant, and Kimball reported no increased risk for AMR among presensitized recipients, although sustained elevations of anti‐AT1R were associated with poorer patient outcomes.…”

Section: Discussionmentioning

confidence: 99%

Xenoreactive antibodies and latent fibrin formation in VAD and cardiac transplant recipients can confound the detection and measurement of anti-AT1R antibodies

Oaks

Michel

Downey

et al. 2018

American Journal of Transplantation

View full text Add to dashboard Cite

Autoantibodies to the angiotensin II type 1 receptor (AT1R) are thought to be important in antibody-mediated rejection (AMR), especially in the absence of anti-HLA antibodies. We used a variety of methods to examine the specificity of a commercially available kit designed to quantitate anti-AT1R antibodies. We found that fibrin formation in serum samples from patients awaiting cardiac transplantation with ventricular assist devices (VADs) can produce falsely elevated anti-AT1R values. In addition, absorption studies with a variety of cell lines with or without expression of human AT1R, and those that express xenoantigens, suggest that many of the antibodies detected in the AT1R test system are heterophilic and have reactivity to xenoantigens. Furthermore, we provide data that show that reactivity to the sialic acid Neu5Gc is a common finding among samples that are highest in anti-AT1R levels. We conclude that a common laboratory method for quantitation of anti-AT1R antibodies is nonspecific and overestimates the frequency of true positives. A reevaluation of the role that anti-AT1R antibodies play in allograft function and patient outcomes is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Xenoreactive antibodies and latent fibrin formation in VAD and cardiac transplant recipients can confound the detection and measurement of anti-AT1R antibodies

Oaks

Michel

Downey

et al. 2018

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…140 To be noted, some non-HLA DSA, like, angiotensin-II type-1 receptor (commonly known as AT1R), anti-glutathione-Stransferase T1 (commonly known as GSTT1), MHC class-I related chain A (commonly known as MICA) antibodies, can also induce acute and chronic graft dysfunction, all of which deserve additional attention. [141][142][143][144] Future research is required in the exploration of mechanisms to identify pathologic DSA, development of monitoring and diagnostic tools, appropriate risk stratification, and minimization for de novo DSA by proper use of immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

Donor-specific HLA Antibodies in Solid Organ Transplantation: Clinical Relevance and Debates

Wang¹,

Wang²,

Wang³

et al. 2019

Exploratory Research and Hypothesis in Medicine

View full text Add to dashboard Cite

Both preformed and de novo DSA represent a significant obstacle to transplantation Preformed DSA before transplantation Exposure to "non-self" HLA molecules, as after blood transfusion, pregnancy or sensitization events, can lead to the development of preformed anti-HLA antibodies. 10 Transfusion avoidance or the use of HLA-matched blood may reduce this risk and improve outcomes. 10 Pre-existing sensitization to HLA-DSA may be a contraindication to transplantation due to the increased risk of acute rejection, delayed graft function, and decreased graft survival. 11-15 In support of this observation, pre-transplant DSA significantly

show abstract

“…The presence of pre‐transplant AT 1 R antibodies is an independent risk factor for long‐term graft survival and acute rejection in kidney transplantation (Giral et al., 2013) (Banasik, Boratyńska, Kościelska‐Kasprzak, Kamińska, Bartoszek, et al, 2014). Testing AT 1 R antibodies pre‐transplant may be helpful to stratify the immunological risk of AMR (Lee, Huh, et al, 2015;Lee, Park, et al, 2015). Impact of de novo AT 1 R antibodies post‐transplant has also been studied.…”

Section: Antibodies Against Angiotensin II Type 1 Receptor (At1r)mentioning

confidence: 99%

Impact and production of Non‐HLA‐specific antibodies in solid organ transplantation

Zhang

Reinsmoen

2020

Int J Immunogenetics

View full text Add to dashboard Cite

Abbreviations: AT 1 R, angiotensin II type 1 receptor; DSA, donor-specific antibody;ELISA, enzyme-linked immunosorbent assay; ET A R, endothelin type A receptor; FSGS, focal segmental glomerulosclerosis; GPCR, G protein-coupled receptor; HLA, human leucocyte antigen. AbstractOrgan transplantation is an effective way to treat end-stage organ disease. Extending the graft survival is one of the major goals in the modern era of organ transplantation. However, long-term graft survival has not significantly improved in recent years despite the improvement of patient management and advancement of immunosuppression regimen. Antibody-mediated rejection is a major obstacle for long-term graft survival. Donor human leucocyte antigen (HLA)-specific antibodies were initially identified as a major cause for antibody-mediated rejection. Recently, with the development of solid-phase-based assay reagents, the contribution of non-HLA antibodies in organ transplantation starts to be appreciated. Here, we review the role of most studied non-HLA antibodies, including angiotensin II type 1 receptor (AT 1 R), K-α-tubulin and vimentin antibodies, in the solid organ transplant, and discuss the possible mechanism by which these antibodies are stimulated. K E Y W O R D SAT 1 R, collagen V, HLA, K-α1-tubulin, non-HLA antibody, transplant, vimentin How to cite this article: Zhang X, Reinsmoen NL. Impact and production of Non-HLA-specific antibodies in solid organ transplantation. Int J Immunogenet. 2020;47:235-242.

show abstract

Clinical Implications of Angiotensin II Type 1 Receptor Antibodies in Antibody-mediated Rejection Without Detectable Donor-specific HLA Antibodies After Renal Transplantation

Cited by 24 publications

References 12 publications

Xenoreactive antibodies and latent fibrin formation in VAD and cardiac transplant recipients can confound the detection and measurement of anti-AT1R antibodies

Xenoreactive antibodies and latent fibrin formation in VAD and cardiac transplant recipients can confound the detection and measurement of anti-AT1R antibodies

Donor-specific HLA Antibodies in Solid Organ Transplantation: Clinical Relevance and Debates

Impact and production of Non‐HLA‐specific antibodies in solid organ transplantation

Contact Info

Product

Resources

About